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INTRODUCTION
A conflicts of interest (COI) is ‘a set of conditions in which 
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ABSTRACT
INTRODUCTION The tobacco control community has raised some 
concerns about whether studies on electronic cigarettes 
(e-cigarettes) published in scientific journals hide conflicts of 
interest (COI) and whether such reports are biased. This study 
assessed potential COI in the e-cigarette scientific literature.
METHODS Cross-sectional study was conducted on e-cigarette 
publications indexed in PubMed up to August 2014. We 
extracted information about the authors (affiliations, location, 
etc.), publication characteristics (type, topic, subject, etc.), 
results and conclusions, presence of a COI statement, and 
funding by and/or financial ties to pharmaceutical, tobacco, 
and/or e-cigarette companies. An algorithm to determine the 
COI disclosure status was created based on the information 
in the publication. Prevalence ratios (PRs) and confidence 
intervals (CIs) were calculated to identify associations with 
COI disclosure, controlling for several independent variables. 
RESULTS Of the 404 publications included in the analysis, 37.1% 
(n=150) had no COI disclosure statement, 38.6% declared 
no COI, 13.4% declared potential COI with pharmaceutical 
companies, 3.0% with tobacco companies, and 10.6% with 
e-cigarette companies. The conclusions in publications with 
COI, which were mainly tied to pharmaceutical companies, 
were more likely to be favourable to e-cigarette use (PR=2.23; 
95% CI: 1.43–3.46). Publications that supported the use of 
e-cigarettes for both harm reduction (PR=1.81; 95%CI: 1.14–
2.89) and smoking cessation (PR=2.02; 95% CI: 1.26–3.23) 
were more likely to have conclusions that were favourable to 
e-cigarettes. 
CONCLUSIONS One-third of the publications reporting studies 
on e-cigarettes did not have a COI disclosure statement, and 
this proportion was even higher in news articles, editorials 
and other types of publications. Papers with conclusions that 
were favourable to e-cigarette use were more likely to have 
COI. Journal editors and reviewers should consider evaluating 
publications, including funding sources, to determine whether 
the results and conclusions may be biased.
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professional judgment concerning a primary interest 
(such as a patient’s welfare or the validity of research) 
tends to be unduly influenced by a secondary interest 
(such as financial gain)’1. COI occurs when authors, 
reviewers or editors have interests that are not fully 
apparent and that could influence their judgment on 
what they publish or review2,3. 
Efforts to provide transparency regarding COIs 
date back to 19844,5. In recent years, COI disclosure 
policies have become a regular part of biomedical 
research. The International Committee of Medical 
Journal Editors’ guidelines recommend that 
authors should disclose the study’s funding sources 
and any financial ties to core companies, such as 
pharmaceutical or tobacco companies6.  In addition, 
since 2013 the Committee on Publication Ethics 
(COPE) established two levels of obligation for 
its members. The first is a Code of Conduct which 
Journal Editors are expected to practise (and will 
consider complaints against members who do not 
follow it), and the second is a set of Best Practice 
recommendations, which are voluntary, but are 
suggested to include into the journal’s policies and 
practices7. Among these practices, ‘Editors should 
have systems for managing COI by authors and 
reviewers, as well as their own COI, including their 
staff and editorial board members’7.
Nevertheless, evidence shows that tobacco 
research sponsored by pharmaceutical4 or tobacco 
companies may be biased8-11 due to vested economic 
interests. In the 1970s, tobacco companies 
downplayed the harm of second-hand smoke, for 
example, by hiding damaging data and distorting 
research findings9-12. Nowadays, the four major 
tobacco companies are involved in the manufacturing 
of electronic cigarettes (also called e-cigarettes). 
Considering that this electronic device resembles 
cigarette use, it is plausible that the same strategies 
could be used for manipulating the scientific evidence 
about the use of this relatively new product12. In fact, 
some in the scientific community are concerned that 
publications on e-cigarettes may hide COI and thus 
their results could be biased13-16. A systematic review 
of the health effects of e-cigarettes revealed that 34% 
of the 76 reviewed articles had declared COI, mostly 
funding from the manufacturers of e-cigarettes 
or authors who had acted as consultants for the 
manufacturers of smoking cessation treatments17. 
Another systematic review that addressed passive 
exposure to e-cigarettes showed that 30% of the 40 
reviewed papers had potential COI18. One report on 
the ‘evidence update’ of e-cigarettes19 claimed that 
‘e-cigarettes are 95% less harmful to health than 
normal cigarettes’; this claim was contested because 
its conclusions appeared to be biased due to COI12,15. 
That report also raised serious questions because of 
its lack of a peer-review process, and thus several 
organizations put this issue in the spotlight12,19. 
Some journals do not accept manuscripts with 
links to tobacco companies20. This decision has 
been criticised by some authors, who argue that 
these journals have passed a strong rule without 
enough evidence to justify it and that the journals 
themselves have some countervailing reasons to 
do so20. Although full disclosure of financial ties 
is common in scientific journals when publishing 
an original report, it seems to be less a priority for 
other types of articles, such as commentaries, news 
items, etc7. There are hundreds of publications about 
e-cigarettes, but, considering its novelty, less than 
half are original articles or reviews, with the rest 
being mainly notes, editorials or opinions21. 
Thus, our objective was to conduct an assessment 
of potential COI in the emergent scientific literature 
on e-cigarettes. Specifically, we aimed to analyse the 
declaration of potential COI in any type of publication 
(original and non-original reports), according to the 
criteria proposed by COPE. 
METHODS 
We performed a search on PubMed (www.pubmed.
gov) to identify all publications on e-cigarettes listed 
in Medline and indexed until August 2014. We 
included all types of publications whose primary or 
secondary aim or topic was related to e-cigarettes. 
The full search strategy used was as follows: 
(‘electronic cigarettes’[All Fields] OR e cig[All Fields] 
OR e cigar[All Fields] OR e cigarettes[All Fields] OR 
e cigarette[All Fields] OR e cigarette’s[All Fields] 
OR e cigs[All Fields] OR ‘electronic nicotine delivery 
system’[All Fields] OR ‘electronic nicotine delivery 
devices’[All Fields]) AND (‘0001/01/01’[PDAT]: 
‘2014/08/31’[PDAT]). No other restrictions were 
established.
The search returned 445 publications. Five 
pairs of reviewers assessed the title and abstracts 
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(if available) of about 90 publications each. Of 
the retrieved publications, 30 were not related to 
e-cigarettes, 2 were duplicate publications, and 2 
anecdotally mentioned e-cigarettes. Thus, 411 
publications were eligible for full assessment. After 
reading the full text, 7 were excluded: 1 was not 
related to electronic cigarettes, 3 mentioned them as 
a secondary topic with no specific comments, and 3 
were unavailable to retrieve (including unsuccessful 
contact with the corresponding authors); thus, 404 
publications were included in the final analysis 
(Figure 1). 
Some tools were created to extract the information, 
including a protocol to guide the pull out of data, 
an algorithm (Supplementary Figure S1) to assess 
the publication’s disclosure status, and an ad hoc 
Excel spreadsheet to register the information for 
each publication. They were pilot-tested using 5 
full-text publications that were assessed by all of 
the researchers. When there were any questions, the 
reviewers discussed the papers with the assigned 
partner until agreement was reached. If they could 
not come to an agreement, two other researchers 
were assigned and resolved the issue. 
Variable definitions and operationalisation
Based on information in the publication several 
variables were assessed, including information 
about the authors, the publications, COI, results and 
conclusions. 
Authors’ information 
Authors: The surname and initials for all authors 
were collected. 
Institutional affiliation: All affiliations from all the 
authors were considered. This information was 
classified as follows: no affiliations were provided 
for any of the authors; some of the authors had 
Figure 1. PRISMA chart showing the selection of the publications included in the analysis.
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their affiliations specified; all authors had their 
affiliations specified. Affiliations were classified into 
the following categories: 1) academy/university, 2) 
governmental/public agency, 3) health organization, 
4) private company, 5) pharmaceutical company, 
6) tobacco company, 7) e-cigarette company, and 
8) other. If the affiliation was related to more 
than one core company (pharmaceutical, tobacco, 
or e-cigarette companies, PTEC_CO), then it was 
classified based on its main scope (for instance, in 
the case of a tobacco company that also manufactures 
e-cigarettes, it was classified as ‘tobacco company’).
Country of origin: The country with which the 
first author was affiliated was recorded and was 
reclassified according to continent for the analysis.
Publication characteristics 
Year of publication: The search included all 
publications indexed in PubMed up to August 2014 
(publications that were in press when the search was 
conducted were updated to reflect the final date of 
publication).
Type of publication: Publications were classified 
as original article, review, editorial, letter, news, 
commentary, or other, based on the information 
in the full publication; when this information 
was not provided, the classification was based on 
the structure of the publication, following the 
descriptions of different types of publications on the 
journal’s website.
Aim: The presence of a specific research aim was 
captured (no, yes).
Empirical data: The reporting of empirical data was 
determined (no, yes). For publications reporting 
empirical data, they were classified as follows: 1) 
the main topic/s of the study-allowing for multiple 
responses such as  prevalence of use, toxicology 
(chemical analysis), health effects, smoking cessation, 
topography, attitudes and knowledge, regulation and 
marketing, clinical advice, other, and miscellaneous 
(different or mixed topics), and 2) the main subject 
of the study-allowing for multiple responses such as 
no main subject, humans, e-cigarettes themselves, 
including the device, liquids and emissions, 
regulation and marketing, and other.
Conflicts of interest (COI)
COI: The presence of a COI section was determined 
(no, yes), using this or similar wording (e.g. 
competing interests). In addition, we recorded 
whether the authors reported their COI status in 
any section of the publication (no, yes) and the 
literal wording. Also, we recorded whether the 
potential COI reported was related to pharmaceutical 
(P), tobacco (T) and/or electronic cigarette (EC) 
companies (PTEC_CO) (no, yes). 
A c k n o w l e d g m e n t s :  Th e  p r e s e n c e  o f  a n 
acknowledgments section was assessed (no, yes). If 
yes, we recorded whether the authors acknowledged 
any of the PTEC_CO.
Funding: The disclosure of any funding or 
sponsorship for the study (grant, donation, other) 
in any section of the publication was assessed (no, 
yes). If yes, we classified the source(s) of funding 
as being from a university, governmental/public 
organisation, private organisation, PTEC_CO, and/
or other sources.
Financial  t ies:  We determined whether the 
authors had other financial ties to PTEC_CO (no, 
yes) and the type of these financial ties, meaning 
personal payments for:  1) services ,  travel , 
training, etc.; 2) money for patents, conferences, 
etc.; and 3) other financial ties. This information 
was drawn from any part of the publication, 
main affiliation, COI statement, funding and 
acknowledgements.
Overall view of disclosure status: Based on the 
information about the funding sources and the 
authors’ financial ties, we classified the disclosures of 
potential COI into 5 categories as follows: the authors 
did not disclose any COI within the manuscript 
(code 0); the authors disclosed no COI for the study, 
and no funding from any PTEC_CO are mentioned 
(code 1); the authors disclosed no COI for the study, 
but they acknowledged that some of the authors 
or previous studies conducted by the authors 
received funding from PTEC_CO in the past (code 
2); the authors disclosed no COI for the study, but 
acknowledged receiving funding for the study from 
PTEC_CO (code 3); and the authors disclosed COI 
with PTEC_CO (code 4). For multivariate Poisson 
regression analysis, we excluded publications with no 
disclosures (code 0) and collapsed the publications 
into two categories: those that disclosed no COI at 
all (code 1) and those that disclosed any COI (codes 
2–4). 
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Results, conclusions and publication tendency
Results: For empirical publications, the reported 
results were categorised as being ‘favourable’ to 
the use of e-cigarettes, ‘not being favourable to 
their use’, ‘neutral’ (not in favour nor against), or 
‘unclear’ (undefined tendency). The classification 
was done according to the findings provided in the 
study, avoiding any interpretation of them. For the 
analysis, we combined publications in the ‘neutral’ 
and ‘unclear’ categories into one category. 
Conclusions: For all publications, with and without 
results, the specific conclusions in this section, or 
in the abstract if unclear, were also categorised 
as being ‘favourable’ to the use of e-cigarettes, 
‘not being favourable’ to their use, ‘neutral’ or 
‘unclear’. For assessing this variable we searched 
for authors’ conclusions and recommendations in 
the corresponding section, in the discussion section 
or in the abstract if it was not clear, in the case of 
empirical publications, and within the publication for 
non-empirical publications. We also combined the 
‘neutral’ and ‘unclear’ conclusions into one category.
Overall publication tendency: Based on the results 
and conclusions, we determined whether the 
publication showed a tendency to support some of 
the following (multiple responses were possible): 
the use of e-cigarettes for harm reduction (reduction 
of tobacco products by using e-cigarettes), stronger 
regulation of e-cigarettes, and the use of e-cigarettes 
for tobacco smoking cessation.
Statistical analysis
We report the frequency and percentage of COI 
disclosure (codes 0–4), the potential COI with 
PTEC_CO and the tendency of the main conclusions 
of publications with empirical data according to the 
publication characteristics, the main study subjects 
and the topics studied. We also describe the COI 
disclosure (codes 0–4) according to the conclusion 
and the publication tendency, for all publications 
and for empirical studies. In addition, we calculated 
prevalence ratios (PRs) and their 95% confidence 
intervals (CIs) using multivariate Poisson regression 
analysis with robust standard error estimations 
(White-Huber robust standard errors) to identify 
associations with COI disclosure, controlling for the 
continent of the first author, the year of publication, 
empirical data, main subject and main topic. 
RESULTS
A total of 404 publications were analysed. The more 
recent the publication year, the higher the number 
of publications on e-cigarettes, with a tendency 
towards an exponential increase (Supplementary 
Figure S2). Of all publications, 36.9% were original 
articles (Table 1). Almost all (96.0%) were written 
in English; the first author was in North America in 
half of the publications (48.5% of all publications 
were from the USA and 2.2% from Canada), and in 
Europe in a third of them (11.9% of all publications 
were from UK, 6.4% from Italy and 3.5% from 
Greece). Information about the country could not 
be determined in 7.7% of all the publications. The 
most frequent topics were e-cigarette regulation 
and marketing (24.5%) and toxicology (13.1%); 
nevertheless, a high percentage of the publications 
focused on miscellaneous topics, i.e. covering a 
variety of topics in the same publication or not 
addressing specific topics (21.5%). Overall, 41.1% 
of the publications reported empirical data; in these 
publications, the most frequent study subject was 
humans (62.0%).
Table 1 shows the COI disclosures in the 
publications. Of the included publications, 150 
(37.1%) did not include any disclosure related to 
COI, mainly those without empirical data, including 
all 42 of the news articles and 16 of the 25 editorials. 
Another 38.6% of the publications disclosed no COI 
at all; 6.2% stated that there were no COI, but some 
authors had potential COI in previous publications; 
while 4.5% stated that they had no COI, but they 
acknowledged financial support by PTEC_CO. 
Finally, 13.6% of the publications disclosed potential 
COI: 13.4% with pharmaceutical companies, 3.0% 
with tobacco companies, and 10.6% with e-cigarette 
companies.
Table 2 shows the tendencies of the conclusions 
regarding e-cigarettes for the publications that 
had empirical data, both overall and according to 
independent variables (n=164; 2 publications had no 
conclusions). Of these, 55.5% of the publications had 
conclusions that were neutral or unclear, and 22.6% 
had favourable conclusions about e-cigarettes. Most 
of the publications were original articles, so the 
conclusion tendencies were similar to those observed 
in the publications overall. Publications in which the 
main topic was related to smoking cessation were 
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Table 1. Disclosure of conflicts of interest and potential conflicts of interest with core companies (PTEC_COsa)
Total Conflicts of interest disclosure status
































n n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
All publications 404 150 (37.1) 156 (38.6) 25 (6.2) 18 (4.5) 55 (13.6) 54 (13.4) 12 (3.0) 43 (10.6)
Type of 
publication
Original article 149 34 (22.8) 65 (43.6) 13 (8.7) 12 (8.1) 25 (16.8) 24 (16.1) 4 (2.7) 23 (15.4)
Review 44 11 (25.0) 18 (40.9) 4 (9.1) 2 (4.5) 9 (20.5) 10 (22.7) 4 (9.1) 4 (9.1)
Editorial 25 16 (64.0) 8 (32.0) 0 (0.0) 0 (0.0) 1 (4.0) 0 (0.0) 0 (0.0) 0 (0.0)
Letter 35 7 (20.0) 19 (54.3) 1 (2.9) 1 (2.9) 7 (20.0) 5 (14.3) 1 (2.9) 8 (22.9)
News 42 42 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Commentary 20 2 (10.0) 10 (50.0) 4 (20.0) 1 (5.0) 3 (15.0) 6 (30.0) 1 (5.0) 3 (15.0)
Other 89 38 (42.7) 36 (40.4) 3 (3.4) 2 (2.2) 10 (11.2) 9 (10.1) 2 (2.2) 5 (5.6)
Languagec
English 388 140 (36.1) 152 (39.2) 24 (6.2) 18 (4.6) 54 (13.9) 52 (13.4) 12 (13.1) 42 (10.8)
Other 16 10 (62.5) 4 (25.0) 1 (6.3) 0 (0.0) 1 (6.3) 2 (12.5) 0 (0.0) 1 (6.3)
Continent of 
first author
North Americad 205 61 (29.8) 107 (52.2) 4 (2.0) 14 (6.8) 19 (9.3) 14 (6.8) 4 (2.0) 5 (2.4)
Africa 4 3 (75.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (25.0)
Asia 12 8 (66.7) 4 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Europe 137 46 (33.6) 36 (26.3) 20 (14.6) 3 (2.2) 32 (23.4) 36 (26.3) 7 (5.1) 32 (23.4)
Oceania 15 3 (20.0) 6 (40.0) 1 (6.7) 1 (6.7) 4 (26.7) 4 (26.7) 1 (6.7) 5 (33.3)
Unknown 31 29 (93.5) 2 (6.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0)
Main topic
Prevalence 43 14 (32.6) 16 (37.2) 2 (4.7) 4 (9.3) 7 (16.3) 5 (11.6) 1 (2.3) 3 (7.0)
Toxicology 53 22 (41.5) 12 (22.6) 4 (7.5) 4 (7.5) 11 (20.8) 7 (13.2) 1 (1.9) 10 (18.9)
Health effects 39 9 (23.1) 19 (48.7) 3 (7.7) 2 (5.1) 6 (15.4) 5 (12.8) 2 (5.1) 9 (23.1)
Smoking 
cessation
44 10 (22.7) 16 (36.4) 5 (11.4) 1 (2.3) 12 (27.3) 16 (36.4) 2 (4.5) 10 (22.7)
Topography 3 0 (0.0) 3 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Attitudes, 
knowledge
22 7 (31.8) 10 (45.5) 2 (9.1) 1 (4.5) 2 (9.1) 3 (13.6) 1 (4.5) 0 (0.0)
Regulation, 
marketing
99 46 (46.5) 44 (44.4) 3 (3.0) 2 (2.0) 4 (4.0) 3 (3.0) 0 (0.0) 4 (4.0)
Clinical advice 3 1 (33.3) 1 (33.3) 0 (0.0) 0 (0.0) 1 (33.3) 1 (33.3) 0 (0.0) 0 (0.0)
Other 11 3 (27.3) 6 (54.5) 0 (0.0) 1 (9.1) 1 (9.1) 0 (0.0) 1 (9.1) 0 (0.0)
Miscellaneous 87 38 (43.7) 29 (33.3) 6 (6.9) 3 (3.4) 11 (12.6) 14 (16.1) 4 (4.6) 7 (8.0)
Empirical data
Yes 166 37 (22.3) 77 (46.4) 13 (7.8) 12 (7.2) 27 (16.3) 25 (15.1) 5 (3.0) 25 (15.1)
No 238 113 (47.5) 79 (33.2) 12 (5.0) 6 (2.5) 28 (11.8) 29 (12.2) 7 (2.9) 18 (7.6)
Main subjecte 
(n=166)
Humans 103 20 (19.4) 46 (44.7) 7 (6.8) 9 (8.7) 21 (20.4) 20 (19.4) 4 (3.9) 19 (18.4)
Continued
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the most prevalent in terms of having conclusions 
favourable to the use of e-cigarettes.
Table 3 shows the distribution of the types of COI 
disclosures among all publications and among those 
with empirical data, according to the conclusion 
and the publication tendencies. Overall publications 
with conclusions that tended to favour the use of 
e-cigarettes, 36.7% disclosed having potential COI, 
whereas 40.8% of those with conclusions that tended 
to be neutral/unclear disclosed no COI. When we 
consider only the 166 empirical studies, 37.8% 
of those with conclusions that were favourable to 
the use of e-cigarettes disclosed COI, whereas the 
majority of those with conclusions that tended not to 
favour the use of e-cigarettes or that were neutral/
unclear disclosed that they did not have COI (55.6% 
and 50.5%, respectively). Regarding the distribution 
of COI disclosures according to the publication 
tendencies, we observed that 20.5% of the overall 
publications supported the use of e-cigarettes as a 
harm reduction tool, 31.7% supported regulating 
e-cigarettes, and 17.6% supported their use for smoking 
cessation. Among the empirical studies, most that 
supported harm reduction or e-cigarette regulation 
disclosed no COI (40.0% and 52.3%, respectively), 
whereas those publications that supported smoking 
cessation mostly disclosed potential COI.
Table 4 shows the PRs of the publications with 
favourable conclusions about e-cigarettes and the 
Table 2. The tendencies of the main conclusions of 



















142 36 (25.4) 28 (19.7) 78 (54.9)
Review 9 0 (0.0) 0 (0.0) 9 (100.0)




0 0 (0.0) 0 (0.0) 0 (0.0)
Other 8 1 (12.5) 4 (50.0) 3 (37.5)
Languageb
English 161 36 (22.4) 35 (21.7) 90 (55.9)





104 11 (10.6) 29 (27.9) 64 (61.5)
Africa 1 1 (100.0) 0 (0.0) 0 (0.0)
Asia 7 0 (0.0) 3 (42.9) 4 (57.1)
Europe 49 23 (46.9) 4 (8.2) 22 (44.9)
Oceania 3 2 (66.7) 0 (0.0) 1 (33.3)
Total Conflicts of interest disclosure status
































n n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
E-cigarettes 
per se
37 12 (32.4) 15 (40.5) 3 (8.1) 2 (5.4) 5 (13.5) 4 (10.8) 1 (2.7) 5 (13.5)
Regulation, 
marketing
19 3 (15.8) 13 (68.4) 2 (10.5) 0 (0.0) 1 (5.3) 1 (5.3) 0 (0.0) 1 (5.3)
Otherf 7 2 (28.6) 3 (42.9) 1 (14.3) 1 (14.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Table 1. Continued
a PTEC_COs: pharmaceutical (P), tobacco (T) and/or electronic cigarette (EC) companies. b Potential conflicts of interest with core companies are not exclusive.
c There was 1 publication in both English and French that was codified as an English language publication. d All publications were from the United States or Canada.
e Publications with empirical data only. f Other subjects: in vitro studies, animal studies, or other. 
Continued
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publications’ tendencies, estimated from multivariate 
Poisson regression models, according to having a COI 
disclosure, the main topic of research, and the main 
subject studied. Publications with a COI disclosure 
were more likely to have favourable conclusions 
about e-cigarettes (PR=2.23; 95% CI: 1.43–3.46), 
to support its use as a tool for harm reduction 
(PR=1.81; 95% CI: 1.14–2.89), and to support its 
use for smoking cessation (PR=2.02; 95% CI: 1.26–
3.23). Publications about e-cigarette toxicology/
health effects or about smoking cessation/clinical 
advice were more likely to have conclusions that 
favoured the use of e-cigarettes. Furthermore, 
papers in which the main subject was e-cigarettes 
themselves were less likely to have conclusions 
that were favourable to e-cigarettes (PR=0.49; 95% 
CI: 0.29–0.85). Publications with COI related to 
pharmaceutical companies were more likely to have 
favourable conclusions about e-cigarettes (PR=1.59; 
95% CI: 1.05–2.40); this association was not found 
for COI involving other types of companies (data 
not shown). Publications that addressed smoking 
cessation/clinical advice, and other or miscellaneous 
topics, were more likely to support smoking cessation 
(PR=3.10 and 2.71, respectively), whereas papers in 
which the main subject was e-cigarettes themselves 
were less likely to support the use of e-cigarettes for 












Humans 102 31 (30.4) 19 (18.6) 52 (51.0)
E-cigarettes 
per se
36 4 (11.1) 10 (27.8) 22 (61.1)
Regulation, 
marketing
19 0 (0.0) 6 (31.6) 13 (68.4)
Otherd 7 2 (28.6) 1 (14.3) 4 (57.1)
Main topic
Prevalence 36 5 (13.9) 9 (25.0) 22 (61.1)
Toxicology 34 5 (14.7) 7 (20.6) 22 (64.7)
Health effects 20 8 (40.0) 2 (10.0) 10 (50.0)
Smoking 
cessation
16 13 (81.3) 1 (6.3) 2 (12.5)
Topography 3 1 (33.3) 1 (33.3) 1 (33.3)
Attitudes, 
knowledge
21 2 (9.5) 4 (19.0) 15 (71.4)
Marketing, 
regulation
25 0 (0.0) 10 (40.0) 15 (60.0)
Clinical advice 0 0 (0.0) 0 (0.0) 0 (0.0)
Other 7 3 (42.9) 1 (14.3) 3 (42.9)
Miscellaneous 2 0 (0.0) 1 (50.0) 1 (50.0)
Table 2. Continued
a Two publications had no conclusions and thus they were excluded. b There was 
1 publication in both English and French that was codified as an English language 
publication. c All publications were from the United States or Canada. d Other 
subjects: cells, animals, miscellaneous subjects.
Table 3. Disclosure of conflicts of interest (COIs) according to the publication’s conclusions and the tendency to 




















 (code 4 )
n n (%) n (%) n (%) n (%) n (%)
All publications 404 150 (37.1) 156 (38.6) 25 (6.2) 18 (4.5) 55 (13.6)
Conclusion
Favourable 79 11 (13.9) 23 (29.1) 14 (17.7) 2 (2.5) 29 (36.7)
Not favourable 93 33 (35.5) 53 (57.0) 0 (0.0) 2 (2.2) 5 (5.4)
Neutral/unclear 169 64 (37.9) 69 (40.8) 8 (4.7) 14 (8.3) 14 (8.3)
No conclusion 63 42 (66.7) 11 (17.5) 3 (4.8) 0 (0.0) 7 (11.1)
Publication tendencyb
Supports their use for harm 
reduction
83 24 (28.9) 23 (27.7) 11 (13.3) 2 (2.4) 23 (27.7)
Supports regulation 128 55 (43.0) 51 (39.8) 9 (7.0) 4 (3.1) 9 (7.0)
Continued
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We examined the factors associated with reporting 
potential COI in the scientific literature on 
e-cigarettes. We found that over a third of the 
publications did not have any COI disclosures; 




















 (code 4 )
n n (%) n (%) n (%) n (%) n (%)
Supports their use for 
smoking cessation
71 18 (25.4) 18 (25.4) 10 (14.1) 2 (2.8) 23 (32.4)
Empirical studies 166 37 (22.3) 77 (46.4) 13 (7.8) 12 (7.2) 27 (16.3)
Conclusion
In favour 37 2 (5.4) 11 (29.7) 8 (21.6) 2 (5.4) 14 (37.8)
Not in favour 36 14 (38.9) 20 (55.6) 0 (0.0) 1 (2.8) 1 (2.8)
Neutral/unclear 91 20 (22.0) 46 (50.5) 5 (5.5) 9 (9.9) 11 (12.1)
No conclusion 2 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0)
Publication tendencyb
Supports their use for harm 
reduction
25 3 (12.0) 10 (40.0) 4 (16.0) 2 (8.0) 6 (24.0)
Supports regulation 44 13 (29.5) 23 (52.3) 5 (11.4) 2 (4.5) 1 (2.3)
Supports their use for 
smoking cessation
30 3 (10.0) 8 (26.7) 6 (20.0) 2 (6.7) 11 (36.6)
Table 3. Continued
a PTEC_COs: pharmaceutical (P), tobacco (T) and/or electronic cigarette (EC) companies. b Multiple responses were possible. 
Table 4. Conclusions and publications’ tendencies that favour e-cigarettes use according to conflicts of interest 
disclosure, the main research topic, and the main subject of the study
Publications’ tendency
Conclusion that 
favour use of 
e-cigarettes 
Supports their use 
for harm reduction Supports regulation
Supports their 
use for smoking 
cessation
Variables PR 95% CI PR 95% CI PR 95% CI PR 95% CI
Conflicts of interest disclosure (yesa) 2.23 1.43–3.46 1.81 1.14–2.89 0.78 0.49–1.24 2.02 1.26–3.23
Main topic 
Prevalence/topography/attitudes Ref.
Toxicology/health effects 2.04 1.03–4.05 1.82 0.67–4.93 0.70 0.30–1.63 1.20 0.53–2.71
Smoking cessation/clinical advice 3.01 1.55–5.85 2.58 0.96–6.91 0.48 0.16–1.42 3.10 1.53–6.28
Regulation/marketing 2.08 0.91–4.78 2.97 1.05–8.44 1.31 0.55–3.11 2.48 0.90–6.85
Other/miscellaneous 1.97 0.86–4.51 2.34 0.82–6.73 1.27 0.49–3.28 2.71 1.13–6.50
Main subject 
No subject Ref.
Humans 0.89 0.43–1.87 0.94 0.44–2.00 0.54 0.23–1.26 0.85 0.36–2.00
E-cigarettes per se 0.49 0.29–0.85 0.58 0.34–0.98 0.88 0.50–1.53 0.30 0.15–0.60
Regulation, marketing 0.38 0.11–1.23 0.34 0.11–1.00 0.89 0.42–1.87 NAb     NAb
Other 0.60 0.22–1.68 0.83 0.24–2.82 0.42 0.07–2.71 0.25 0.04–1.36
PR: Prevalence ratios were estimated by Poisson regression adjusted for main topic, main subject, empirical data, continent of the first author, and publication year.
a Yes: This includes codes 2–4 (Supplementary Figure S1). b NA: Not applicable (i.e. the values were very unstable due to limited data).
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of publications. Authors who had COI (disclosed 
or not) and publications in which the main topics 
included toxicology/health effects or smoking 
cessation/clinical advice were more likely to 
report favourable conclusions about e-cigarettes. 
In contrast, studies in which the main subject was 
e-cigarettes themselves were less likely to have 
favourable conclusions about e-cigarettes. There are 
a few possible explanations for these findings. First, 
the authors who published studies with favourable 
conclusions about e-cigarettes could have some ties 
to PTEC_CO. These authors may have framed the 
research question, conducted the study, or reported 
the results and conclusions, either consciously or 
unconsciously with the interests of their sponsors in 
mind. Second, it is possible that the authors failed 
to disclose their sponsorship or research constraints, 
and the editors were not as strict as with studies that 
reported non-favourable conclusions.
We found that the conclusions of reports on 
e-cigarettes are associated with their authors’ 
COI. In addition, we observed that publications 
that supported the use of e-cigarettes for smoking 
reduction and smoking cessation were more likely 
to be from authors with COI with PTEC_CO. Our 
study shows that publications that report favourable 
conclusions about e-cigarettes come from authors 
who had received financial support from PTEC_
CO. This pattern is seen in publications with both 
empirical and non-empirical data. 
A systematic review of the prevalence of COI 
found that a third of biomedical researchers in 
academic institutions had COI1. Studies measuring 
undisclosed COI suggest that between 43% and 69% 
of study reports and other publications fail to include 
disclosures of COI3. In our study, we found that 
37.1% of publications did not include any disclosure 
about COI. Disclosure only reveals the possibility of 
bias, without providing any guidance for resolving 
it3. Biases introduced by COI are difficult to deal with 
and should be treated like any other confounder that 
could affect the results of a study3; however, treating 
COI as a confounder is challenging. The failure of 
the scientific community to effectively address COI 
has serious repercussions for public health policy7. 
The scientific community must provide transparency, 
supervision and accountability to help ensure that 
research is not biased by undisclosed COI7. Some 
suggested methods for improving the disclosure of 
potential COI include the introduction of clinical 
trial registries, public accessible registers for 
declarations of interest, and the creation of an Ethics 
Centre that monitors and reports the enforcement of 
ethical standards7. A compulsory detailed statement 
of COI, including some of the variables studied in 
this analysis, may disclose them in a more effective 
manner. This would not completely mitigate the risk 
of bias, but it would facilitate a better understanding 
of how COI are related to biases and how they can 
influence research consensus3. 
We also found that the type of publication can 
influence its tendency to e-cigarettes. Practically all 
reviews were neutral in terms of the tone of their 
conclusions, but letters and other non-empirical 
publications were more likely to be either against 
or favourable to the regulation of e-cigarettes. The 
journal characteristics may also influence the results 
and conclusions of the studies, as the quality of 
their reporting may vary according to the journal’s 
standards22. Articles published in peer-reviewed 
journals are generally of higher quality than 
those published in non-peer-reviewed journals2. 
However, we did not include this independent 
variable in our assessment. Additional research is 
needed to clarify possible associations between 
the journal’s quality and the disclosure of COI in 
e-cigarette publications.
There is evidence that financial COI lead to 
systematic bias23,24. In our study, we observed that 
only publications in which the authors reported ties 
with pharmaceutical companies were associated with 
favourable conclusions on e-cigarettes. However, 
we did not find that authors openly reported COI in 
all cases; sometimes, this information was extracted 
based on the author affiliation, funding received 
in previous studies or from the acknowledgments 
section. We observed that some authors reported 
no COI but declared financial support from or 
even were employees of PTEC_CO (code 3 in our 
classification); thus, they did not acknowledge this 
potential COI. Whether non-reporting of COI was 
consciously done or not is beyond the aims of this 
study. Lack of transparency at the time of submission 
on these issues is likely to lead to a perception by 
readers and editors that the research is tainted25, 
thus is must be avoided. 
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Limitations and strengths 
Our analysis was limited to the information reported 
in the papers; thus, any financial ties or other interests 
that were not reported in the paper could not be 
assessed, so the COI may be underestimated. Also, 
not all journals specify whether all their publications 
are peer-reviewed; not conducting peer review 
may contribute to a lack of declaration of potential 
COI. In addition, we only searched publications 
in the PubMed database. However, PubMed is the 
core database for the biomedical sciences. Another 
limitation is the cross-sectional nature of this study, 
so finding causal relationships was beyond the scope 
of the study. In the search strategy, we included 
publications up to August 2014; this time-frame 
represents seven years after e-cigarettes launched 
into the market (2007 to 2014). Nevertheless, given 
the growing number of papers on e-cigarettes, it is 
possible that more recent publications would show 
different tendencies. However, we were interested 
in the situation when e-cigarettes first began to 
gain popularity, so the study period covered those 
years. Since some of the authors of this report have 
conducted or are conducting research on e-cigarettes, 
their judgments could also have some bias. However, 
all publications were assessed by pairs of reviewers 
who achieved a consensus; also, a protocol and 
algorithm were created to facilitate the objective 
assessment of each publication, and the procedures 
were pilot-tested. In addition, we only identified COI 
when authors reported them in any of the sections 
of the papers (including COI, acknowledgments 
and financial sections, as well as the affiliation 
information). This way, we were able to establish 
their ties with pharmaceutical, e-cigarette and 
tobacco companies. Future bibliographic and social 
science studies should be done to explore the several 
sources of COI in e-cigarette publications, besides 
what authors have reported in papers. Moreover, we 
only studied potential COI related to the authors, but 
COI related to the editors and the reviewers might 
also be relevant26. This type of study is difficult to 
design and conduct, since peer review is usually 
blinded and any potential COI are thus unclear. This 
raises the question of whether current journal policies 
are sufficient to ensure objectivity in the publication 
process and whether the current COI definitions and 
restrictions on publication should be expanded.
The study also has some strengths. It pioneered 
new methodology to describe COI according to 
the criteria proposed by the COPE7. In addition, 
it classified COI disclosures into 5 categories and 
created an algorithm to facilitate the evaluation, thus 
increasing internal validity. The algorithm allowed 
us to detect COI that could be misleading or that 
were not well-described. This tool might be useful 
for identifying situations in which authors do not 
correctly report their COI. In addition, the results of 
this study represent an exhaustive review of potential 
COI for a highly relevant topic, taking into account 
several publication-related variables.
CONCLUSIONS
A third of the assessed publications about e-cigarettes 
did not have any COI disclosure, and this proportion 
was even higher in certain kinds of publications, 
such as news, editorials and other types of articles. 
Publications with favourable conclusions about 
e-cigarettes were more likely to include a COI 
disclosure. Furthermore, favourable conclusions 
about e-cigarettes were more frequent in publications 
that had COI declarations related to pharmaceutical 
companies. Journal editors and reviewers should 
consider evaluating publications, including the 
funding sources, to determine whether the results 
and conclusions may be biased and to determine 
whether there are any relationships with PTEC_CO.
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